<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neuropsychopharmacology</journal-id>
<journal-id journal-id-type="iso-abbrev">Neuropsychopharmacology</journal-id>
<journal-title-group>
<journal-title>Neuropsychopharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0893-133X</issn>
<issn pub-type="epub">1740-634X</issn>
<publisher>
<publisher-name>Nature Publishing Group</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28128334</article-id>
<article-id pub-id-type="pmc">5436118</article-id>
<article-id pub-id-type="pii">npp201720</article-id>
<article-id pub-id-type="doi">10.1038/npp.2017.20</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Protein Kinase C <italic>β</italic>: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotic-Induced Weight Gain</article-title>
<alt-title alt-title-type="running">PKC<italic>β</italic> and antipsychotic-induced weight gain</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Rimessi</surname>
<given-names>Alessandro</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="author-notes" rid="note1">
<sup>6</sup>
</xref>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7091-5765</contrib-id>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pavan</surname>
<given-names>Chiara</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="author-notes" rid="note1">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ioannidi</surname>
<given-names>Elli</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nigro</surname>
<given-names>Federica</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Morganti</surname>
<given-names>Claudia</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brugnoli</surname>
<given-names>Alberto</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Longo</surname>
<given-names>Francesco</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gardin</surname>
<given-names>Chiara</given-names>
</name>
<xref ref-type="aff" rid="aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ferroni</surname>
<given-names>Letizia</given-names>
</name>
<xref ref-type="aff" rid="aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Morari</surname>
<given-names>Michele</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vindigni</surname>
<given-names>Vincenzo</given-names>
</name>
<xref ref-type="aff" rid="aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zavan</surname>
<given-names>Barbara</given-names>
</name>
<xref ref-type="aff" rid="aff4">4</xref>
<xref ref-type="author-notes" rid="note2">
<sup>7</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pinton</surname>
<given-names>Paolo</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="author-notes" rid="note2">
<sup>7</sup>
</xref>
<xref ref-type="corresp" rid="caf1">*</xref>
</contrib>
<aff id="aff1"><label>1</label><institution>Department of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara</institution>, Ferrara, <country>Italy</country></aff>
<aff id="aff2"><label>2</label><institution>Unit of Psychiatry, Department of Neurosciences NPSRR, University of Padua</institution>, Padua, <country>Italy</country></aff>
<aff id="aff3"><label>3</label><institution>Department of Medical Sciences, Section of Pharmacology, Neuroscience Center and National Institute of Neuroscience, University of Ferrara</institution>, Ferrara, <country>Italy</country></aff>
<aff id="aff4"><label>4</label><institution>Department of Biomedical Sciences, University of Padua</institution>, Padua, <country>Italy</country></aff>
<aff id="aff5"><label>5</label><institution>Unit of Plastic Surgery, Department of Neurosciences NPSRR, University of Padua</institution>, Padua, <country>Italy</country></aff>
</contrib-group>
<author-notes>
<corresp id="caf1"><label>*</label><institution>Department of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara</institution>, Via Fossato di Mortara 70 (c/o CUBO), Ferrara 44121, <country>Italy</country>, Tel: +0039 0532455802, Fax: +0039 0532455351, E-mail: <email>pnp@unife.it</email></corresp>
<fn fn-type="equal" id="note1">
<label>6</label>
<p>These authors contributed equally to this work.</p>
</fn>
<fn fn-type="equal" id="note2">
<label>7</label>
<p>These authors share senior co-authorship.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<month>06</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epreprint">
<day>27</day>
<month>01</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>15</day>
<month>02</month>
<year>2017</year>
</pub-date>
<volume>42</volume>
<issue>7</issue>
<fpage>1491</fpage>
<lpage>1501</lpage>
<history>
<date date-type="received">
<day>08</day>
<month>10</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>03</day>
<month>01</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>21</day>
<month>01</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2017 American College of Neuropsychopharmacology</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>American College of Neuropsychopharmacology</copyright-holder>
</permissions>
<abstract>
<p>Antipsychotic drugs are currently used in clinical practice for a variety of mental disorders. Among them, clozapine is the most effective medication for treatment-resistant schizophrenia and is most helpful in controlling aggression and the suicidal behavior in schizophrenia and schizoaffective disorder. Although clozapine is associated with a low likelihood of extrapyramidal symptoms and other neurological side effects, it is well known for the weight gain and metabolic side effects, which expose the patient to a greater risk of cardiovascular disorders and premature death, as well as psychosocial issues, leading to non-adherence to therapy. The mechanisms underlying these iatrogenic metabolic disorders are still controversial. We have therefore investigated the <italic>in vivo</italic> effects of the selective PKC<italic>β</italic> inhibitor, ruboxistaurin (LY-333531), in a preclinical model of long-term clozapine-induced weight gain. Cell biology, biochemistry, and behavioral tests have been performed in wild-type and PKC<italic>β</italic> knockout mice to investigate the contribution of endogenous PKC<italic>β</italic> and its pharmacological inhibition to the psychomotor effects of clozapine. Finally, we also shed light on a novel aspect of the mechanism underlying the clozapine-induced weight gain, demonstrating that the clozapine-dependent PKC<italic>β</italic> activation promotes the inhibition of the lipid droplet-selective autophagy process. This paves the way to new therapeutic approaches to this serious complication of clozapine therapy.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>